Form 8-K - Current report:
SEC Accession No. 0001193125-25-145242
Filing Date
2025-06-24
Accepted
2025-06-24 07:05:20
Documents
15
Period of Report
2025-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d838043d8k.htm   iXBRL 8-K 59585
2 EX-99.1 d838043dex991.htm EX-99.1 25522
7 GRAPHIC g838043g0624072140673.jpg GRAPHIC 5230
  Complete submission text file 0001193125-25-145242.txt   256653

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvmdw-20250623.xsd EX-101.SCH 4426
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvmdw-20250623_def.xml EX-101.DEF 13415
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmdw-20250623_lab.xml EX-101.LAB 22307
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmdw-20250623_pre.xml EX-101.PRE 14319
17 EXTRACTED XBRL INSTANCE DOCUMENT d838043d8k_htm.xml XML 5895
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 251066671
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)